Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-Center, Prospective, Randomized Controlled Clinical Study of Oral Diammonium Glycyrrhizinate for Attenuating Toxicity and Enhancing Efficacy of CAR-T Cell Therapy

NCT07616271 is registered in ClinicalTrials.gov with Tongji Hospital as lead sponsor.

NCT NCT07616271
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07616271 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-Center, Prospective, Randomized Controlled Clinical Study of Oral Diammonium Glycyrrhizinate for Attenuating Toxicity and Enhancing Efficacy of CAR-T Cell Therapy
Lead sponsor
Tongji Hospital
Phase
Phase 2/3
Overall status
Not yet recruiting
Start date
May 22, 2026
Completion date
May 31, 2030
Enrollment
21 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

patients with large b-cell lymphoma receiving car-t cell therapy